Impact and predictors of quality of life in adults diagnosed with a genetic muscle disorder: a nationwide population-based study.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jun 2022
Historique:
accepted: 18 11 2021
pubmed: 28 11 2021
medline: 18 5 2022
entrez: 27 11 2021
Statut: ppublish

Résumé

To determine the impact of genetic muscle disorders and identify the sociodemographic, illness, and symptom factors influencing quality of life. Adults (aged 16-90 years) with a confirmed clinical or molecular diagnosis of a genetic muscle disorder identified as part of a nationwide prevalence study were invited to complete an assessment of the impact of their condition. Quality of life was measured using the World Health Organization Quality of Life questionnaire. Impact was measured via the prevalence of symptoms and comparisons of quality of life against New Zealand norms. Multivariate regression models were used to identify the most significant predictors of quality of life domains. 490/596 participants completed the assessment (82.2% consent rate). Quality of life was lower than the general population on physical (t = 9.37 p < 0.0001, d = 0.54) social (t = 2.27 p = 0.02, d = 0.13) and environmental domains (t = 2.28 p = 0.02, d = 0.13), although effect sizes were small. No difference was found on the psychological domain (t = - 1.17 p = 0.24, d = 0.07). Multivariate regression models (predicting 42%-64% of the variance) revealed personal factors (younger age, being in employment and in a relationship), symptoms (lower pain, fatigue, and sleep difficulties), physical health (no need for ventilation support, fewer activity limitations and no comorbidities), and psychosocial factors (lower depression, anxiety, behavioural dyscontrol and higher self-efficacy, satisfaction with health care and social support) contributed to improved quality of life. A range of factors influence the quality of life in adults diagnosed with a genetic muscle disorder and some may serve as targets for multi-faceted intervention.

Identifiants

pubmed: 34837601
doi: 10.1007/s11136-021-03046-2
pii: 10.1007/s11136-021-03046-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1657-1666

Subventions

Organisme : health research council of new zealand
ID : HRC14/399

Investigateurs

Alice Theadom (A)
Kelly Jones (K)
Braden Te Ao (BT)
Kerry Walker (K)
Miriam Rodrigues (M)
Richard Roxburgh (R)
Gina O'Grady (G)
Priya Parmar (P)
Chris Higgins (C)
Valery Feigin (V)
Annemarei Ranta (A)
Rita Krishnamurthi (R)
Alain Vandal (A)
Paul Brown (P)
Donald Love (D)
Jenny Stewart (J)
Gemma Poke (G)
Graeme Hammond-Tooke (G)

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Cardamone, M., Darras, B. T., & Ryan, M. M. (2011). Inherited myopathies and muscular dystrophies. Seminars in Neurology, 28(2), 250–259.
doi: 10.1055/s-2008-1062269
Graham, C. D., Rose, M. R., Grunfeld, E. A., Kyle, S. D., & Weinman, J. (2011). A systematic review of quality of life in adults with muscle disease. Journal of Neurology, 258(9), 1581–1592.
doi: 10.1007/s00415-011-6062-5
Walklet, E., Muse, K., Meyrick, J., & Moss, T. (2016). Do Psychosocial Interventions Improve Quality of Life and Wellbeing in Adults with Neuromuscular Disorders? A Systematic Review and Narrative Synthesis. Journal of Neuromuscular Disorders, 3(3), 347–362.
doi: 10.3233/JND-160155
Haas, B. K. (1999). A multidisciplinary concept analysis of quality of life. Western Journal of Nursing Research, 21(6), 728–742.
doi: 10.1177/01939459922044153
World Health Organisation Quality of Life [ https://www.who.int/tools/whoqol ]
Jacques, M. F., Stockley, R. C., Onambele-Pearson, G. L., Reeves, N. D., Stebbings, G. K., Dawson, E. A., Groves, L., & Morse, C. I. (2019). Quality of life in adults with muscular dystrophy. Health and Quality of Life Outcomes. https://doi.org/10.1186/s12955-019-1177-y
doi: 10.1186/s12955-019-1177-y pubmed: 31307472 pmcid: 6632211
Bos, I., Wynia, K., Almansa, J., Drost, G., Kremer, B., & Kuks, J. (2019). The prevalence and severity of disease-related disabilities and their impact on quality of life in neuromuscular diseases. Disability and Rehabilitation, 41(14), 1676–1681.
doi: 10.1080/09638288.2018.1446188
Theadom, A., Rodrigues, M., Poke, G., O’Grady, G., Love, D., Hammond-Tooke, G., Parmar, P., Baker, R., Feigin, V., Jones, K. . Te., Ao, B., Ranta, A., Roxburgh, R., On behalf of the MDPrev Research Group. (2019). A nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology, 52(3–4), 128–135.
doi: 10.1159/000494115
Norwood, F. L. M., Harling, C., Chinnery, P. F., Eagle, M., Bushby, K., & Straub, V. (2009). Prevalence of genetic muscle disease in Northern England: In-depth analysis of a muscle clinic population. Brain, 132(11), 3175–3186.
doi: 10.1093/brain/awp236
Bowling, A. (2005). Mode of questionnaire administration can have serious effects on data quality. Journal of Public Health, 27(3), 281–291.
doi: 10.1093/pubmed/fdi031
Jones, K. M., O’Grady, G., Rodrigues, M. J., Ranta, A., Roxburgh, R. H., Love, D. R., Theadom, A., On behalf of the MDPrev Research Group. (2018). Impacts for children living with genetic muscle disorders and their parents—findings from a population-based study. Journal of Neuromuscular Disorders, 5(3), 341–352.
doi: 10.3233/JND-170287
WHOQOLGroup. (1998). Development of the world health organisation WHOQOL-BREF quality of life assessment. Psychological Medicine, 28, 551–558.
doi: 10.1017/S0033291798006667
World Health Organisation. (1996). WHOQOl-BREF Introduction, administration, scoring and generic version of the assessment. World Health Organisation.
Krägeloh, C. U., Billington, R., Hsu, P. H., Feng, X. J., Medvedev, O. N., Kersten, P., Landon, J. J., & Siegert, R. (2016). Ordinal-to-interval scale conversion tables and national items for the New Zealand version of the WHOQOL-BREF. PLoS ONE. https://doi.org/10.1371/journal.pone.0166065
doi: 10.1371/journal.pone.0166065 pubmed: 27812203 pmcid: 5094704
Vandervelde, L., Van den Bergh, P. Y., Goemans, N., & Thonnard, J. L. (2009). Activity limitations in patients with neuromuscular disorders: A responsiveness study of the ACTIVLIM questionnaire. Neuromuscular Disorders, 19(2), 99–103.
doi: 10.1016/j.nmd.2008.11.004
[ http://www.rehab-scales.org/activlim-rasch-analysis-neuromuscular-disorders.html ]
Krupp, L. B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46(10), 1121–1123.
doi: 10.1001/archneur.1989.00520460115022
Measuring Quality of Life in Neurological Disorders, Final Report of the NeuroQOL Study [ http://www.neuroqol.org/Resources/Resources%20documents/NeuroQOL-Final%20report-2013.pdf ]
Cella, D., Lai, J. S., Nowinski, C. J., Victorson, D., Peterman, A., Miller, D., Bethoux, F., Heinemann, A., Rubin, S., Cavazos, J. E., Reder, A. T., Sufit, A. T., Simuni, T., Holmes, G. L., Siderowf, A., Wojna, V., Bode, R., McKinney, N., Podrabsky, T., … Moy, C. (2012). Brief measures of health-related quality of life for clinical research in neurology. Neurology, 78(23), 1860–1867.
doi: 10.1212/WNL.0b013e318258f744
Zimet, G. D., Dahlem, N. W., Zimet, S. G., & Farley, G. K. (1988). The multidimensional scale of perceived social support. Journal of Personality Assessment, 52, 30–41.
doi: 10.1207/s15327752jpa5201_2
Chen, G., Gully, S. M., & Eden, D. (2001). Validation of a new general self-efficacy scale. Organizational Research Methods. https://doi.org/10.1177/109442810141004
doi: 10.1177/109442810141004
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67(6), 361–370.
doi: 10.1111/j.1600-0447.1983.tb09716.x
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research, 28(2), 193–213.
doi: 10.1016/0165-1781(89)90047-4
Hopkins, W.G. (2002). A scale of magnitudes for effect statistics. In: A New View of Statistics. www.sportsci.org/resource/stats/effectmag.html
Merluzzi, T. V., Pustejovsky, J. E., Philip, E. J., Sohl, S. J., Berendsen, M., & Salsmanc, J. M. (2019). Interventions to enhance self-efficacy in cancer patients: A meta-analysis of randomized controlled trials. Psycho-Oncology, 28(9), 1781–1790.
doi: 10.1002/pon.5148
Dong, D., Chong, M. K., & Wu, Y. (2020). Gender differences in quality of life among patients with myasthenia gravis in China. Health and Quality of Life Outcomes. https://doi.org/10.1186/s12955-020-01549-z
doi: 10.1186/s12955-020-01549-z pubmed: 32883289 pmcid: 7470440
Orsini, M., Carolina, A., Ferreira, A. F., de Assis, A., Magalhães, T., Teixeira, S., Bastos, V. H., Marinho, V., Oliveira, T., Fiorelli, R., Oliverira, A. B., & de Freitas, M. R. G. (2018). Cognitive impairment in neuromuscular diseases: A systematic review. Neurology international, 10(2), 7473.
doi: 10.4081/ni.2018.7473
Burns, T. M., Graham, C. D., Rose, M. R., & Simmons, Z. (2012). Quality of life and measures of quality of life in patients with neuromuscular disorders. Muscle and Nerve, 46, 9–25. https://doi.org/10.1002/mus.23245
doi: 10.1002/mus.23245 pubmed: 22644588
Bann, C. M., Abresch, R. T., Biesecker, B., Conway, K. C., Heatwole, C., Peay, H., Scal, P., Strober, J., Uzark, K., Wolff, J., Margolis, M., Blackwell, A., Street, N., Montesanti, A., & Bolen, J. (2015). Measuring quality of life in muscular dystrophy. Neurology, 84(10), 1034–1042.
doi: 10.1212/WNL.0000000000001336
Powell, P. A., Carlton, J., Buckley-Woods, H., & Mazzone, P. (2020). Measuring quality of life in Duchenne muscular dystrophy: A systematic review of the content and structural validity of commonly used instruments. Health and Quality of Life Outcomes. https://doi.org/10.1186/s12955-020-01511-z
doi: 10.1186/s12955-020-01511-z pubmed: 32746836 pmcid: 7397669

Auteurs

Alice Theadom (A)

National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, 90 Akoranga Dr, Northcote, 0627, New Zealand. alice.theadom@aut.ac.nz.

Miriam Rodrigues (M)

Neurology Department, Auckland City Hospital, Auckland, New Zealand.

Annemarei Ranta (A)

Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

Gemma Poke (G)

Genetic Health Service NZ, Capital and Coast District Health Board, Wellington, New Zealand.

Donald Love (D)

Diagnostic Genetics, LabPLUS, Auckland City Hospital, Auckland, New Zealand.

Kelly Jones (K)

National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, 90 Akoranga Dr, Northcote, 0627, New Zealand.

Braden Te Ao (BT)

National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, 90 Akoranga Dr, Northcote, 0627, New Zealand.
Population Health, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand.

Graeme Hammond-Tooke (G)

Brain Health Research Centre, University of Otago, Dunedin, New Zealand.

Priya Parmar (P)

National Institute for Stroke and Applied Neurosciences, Auckland University of Technology, 90 Akoranga Dr, Northcote, 0627, New Zealand.
Department of Biostatistics and Epidemiology, Faculty of Health and Environmental Studies, Auckland University of Technology, Auckland, New Zealand.

Gina O'Grady (G)

Paediatric Neuroservices, Starship Children's Health, Auckland District Health Board, Auckland, New Zealand.

Richard Roxburgh (R)

Neurology Department, Auckland City Hospital, Auckland, New Zealand.
School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH